BriaPro Therapeutics (2/3 owned by BriaCell) reports net loss of $519,804 for 9 months, cash only $1

BriaCell Therapeutics Corp.

Net loss of $519,804 for nine months ended April 30, 2025 vs. $316,517 in prior year period.
Accumulated deficit $960,013; cash and cash equivalents $1.
Due to related parties (BriaCell group) $937,432, up from $424,654 at July 31, 2024.
Warrant liability revalued to $176,409 from $149,841; change in fair value gain of $26,568.
Going concern uncertainty: company has not commenced commercial operations and expects further losses.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.